Is PPCB up or down today?
PPCB is down 9.89% today, last at 1.64. This stock moved -9.89% versus the prior close.
PPCB · PPCB
PPCB (PPCB) is trading at 1.64, down 9.89% on the session. PPCB carries a 14-day RSI of 21, and trades below its 50-day average. Over the past month it is down 66.62%.
Leading the coverage: “Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients” (Yahoo, 6d ago). PPCB is -22.27% since story.
PPCB trades on a trailing P/E of 32.8 and is running 60.70% behind the S&P 500 over the same stretch.
Analyst firms are mostly reiterating — no strong directional shift lately.
PPCB is down 9.89% today, last at 1.64. This stock moved -9.89% versus the prior close.
Leading the coverage: “Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients” (Yahoo, 6d ago). PPCB is -22.27% since story. Dominant story: Propanc Biopharma Inc (PPCB) Stock Price, Quote, News & History - Benzinga (2 sources, neutral) RSI is 21 — oversold (beaten down) Price below 50-day average — short-term weakness Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Loaded: May 2026 – Nov 2026 (125 days) · Drag or scroll left for earlier dates
Propanc Biopharma, Inc. (PPCB) stock price, news, quote and history - Yahoo Finance UK
Propanc Biopharma, Inc. (PPCB) stock price, news, quote and history - Yahoo Finance Australia
Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer
Propanc Biopharma, Inc. (PPCB) Seasonal returns chart - Yahoo Finance UK
Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients